Liu 2008d.

Methods	Allocation: randomised, lottery. Blindness: unclear. Duration: eight weeks. Design: parallel. Setting: inpatient, China.
Participants	Diagnosis: schizophrenia (CCMD‐3). PANSS of 60 or more. N = 72. Age: aripiprazole group: 16～49 years, mean = (33.27 ± 8.21) years; risperidone group: 15～42 years, mean = (30.94 ± 8.77) years. Gender: aripiprazole group: 20 male, 17 female; risperidone group: 19 male, 16 female. History: aripiprazole group: 0.25～3 years, mean = (1.54 ± 0.74) years; risperidone group: 0.25～2.5 years, mean = (1.98 ± 0.81) years. Age at onset not reported.
Interventions	1. Aripiprazole: Dose range: 5‐30 mg/day. Mean= (21.67 ± 1.12) mg/day. N = 37. 2. Risperidone: Dose range: 1‐6 mg/day. Mean= (4.56 ± 1.24) mg/day. N = 35.
Outcomes	Global state: PANSS score decreased rate (recovery: > 75%, markedly improved: 50%‐75%, improved: 25%‐50%, no effect: < 25%). Mental state: PANSS total score, PANSS positive subscale score, PANSS negative subscale score, PANSS general pathological subscale score. WAI‐RC (Wechsler adult intelligence scale) score. WMS (Wechsler memory scale ) score. Adverse effects. Unable to use ‐ Cognitive functioning: WMS subscale scores ‐ unvalidated subscale.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised, lottery.
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not reported.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear if outcome was assessed blindly.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No incomplete data.
Selective reporting (reporting bias)	High risk	Data on TESS total score were missing.
Other bias	Low risk	None obvious.